ASH Poster Walks
ASH Annual Meeting Poster Walks highlight cutting-edge emerging science in hematology during the meeting. A total of seven “walks” will be featured during the meeting, with some taking place virtually and others taking place in person in collaboration with the Blood Journal Studio. In general, both the virtual and in-person Poster Walks can contain up to six posters and are designed to include a brief overview of the selected abstracts, followed by an interactive question-and-answer period between the session organizers, abstract authors, and audience.
ASH Poster Walk on Beyond Acute Vaso-Occlusion: Emerging Mechanisms and Phenotypes of Chronic Pain in Sickle Cell Disease Hosted by Blood Red Cells & Iron
Chronic pain is one of the most common and disabling complications of sickle cell disease, yet it remains highly variable between patients and is not fully explained by traditional markers of disease severity. Recent research has expanded our understanding of the biological, neurological, and clinical mechanisms that contribute to chronic pain, including central sensitization, neurovascular dysfunction, patient-reported outcomes, neuroimaging, and novel treatment approaches. This Poster Walk will bring together emerging research that highlights these advances and their potential to improve patient care. By showcasing innovative studies from basic, translational, and clinical investigators, the session will provide attendees with a broad overview of current progress, encourage discussion across disciplines, and identify opportunities for future research and collaboration. Participants will leave with a better understanding of the evolving science of chronic pain in sickle cell disease and how these findings may influence future clinical practice, research, and therapeutic development.
Chair:
Daniel Sop, PhD
Virginia Commonwealth University
Richmond, VA
Patrick Gallagher, MD
Nationwide Children's Hospital / Ohio State University
Columbus, OH
Speakers:
Slimane Allali, MD, PhD
Paris, France
Pain at Steady State in Children with Sickle Cell Disease Is Correlated with Various Inflammatory Cytokines
Adekunle Emmanuel Alagbe, MD, PhD
Pittsburgh, PA
Riociguat Reduces Inflammatory Cytokines in Sickle Cell Disease: Associations with Pain and Cardiac Function in the Sterio-SCD Trial
Noor Alzraikat, MD
Atlanta, GA
Variation in Transfusion Practices in Patients with Sickle Cell Disease Hospitalized for Acute Pain: A Secondary Analysis of the START Trial
Joel Dzidzorvi Kwame Disu, BSc, MSc
Pittsburgh, PA
Neural Correlates of Central Sensitization Differentiate Pain Phenotypes in Sickle Cell Disease
Claudia Morris, MD
Atlanta, GA
Intravenous L-Citrulline Increases Plasma Arginine Concentration in Patients with Sickle Cell Disease Hospitalized with Acute Pain
ASH Poster Walk on Beyond the Algorithm: The Next Era of Artificial Intelligence in Hematology
Artificial intelligence is rapidly expanding across all facets of hematology, including diagnosis, image analysis, risk stratification, prognostication, clinical decision support, therapeutic selection, clinical trial matching, drug discovery, and healthcare delivery. Traditional machine learning, deep learning, computer vision, and natural language processing continue to generate important advances, while the emergence of generative AI, large language models, AI agents, and agentic frameworks is creating new opportunities to synthesize complex data and support increasingly sophisticated clinical and research workflows. This Poster Walk will highlight cutting-edge applications of AI across malignant and classical hematology, with particular attention to generative AI and emerging agentic systems.
Chair:
David Swoboda, MD
Tampa General Hospital
Tampa, FL
Speakers:
Torsten Haferlach, MD, PhD
Munich, Germany
Explainable AI Integrating Whole-Genome and Whole-Transcriptome Sequencing Classifies 39 Hematologic Disease Categories with High Accuracy
Kuo-Kai Chin, MD
New York, NY
Large Language Model-Enabled Longitudinal Disease Reconstruction and Automated Cohort Generation in Acute Myeloid Leukemia
Gabriel Salzman, MD, PhD
Stanford, CA
Bespoke Hierarchical Analyses of High-Dimensional Spectral Flow Cytometry Data Facilitated by AI Agents
Francesca Dell'Eva, PhD
Rozzano, Italy
Development and Preliminary Evaluation of an Artificial Intelligence-Supported Clinical Decision Support Platform for Personalized Nutritional Care in Hematology
Valerio Lupperger, PhD
Munich, Germany
Artificial Intelligence Can Orchestrate Workflows in Complex Leukemia Diagnostics
ASH Poster Walk on Emerging Toxicities and Predictors in T-Cell–Redirecting Therapies Hosted by Blood Immunology & Cellular Therapy
CAR T-cell therapies and bispecific antibodies have transformed the treatment of lymphoma and multiple myeloma. As their use expands, the toxicity landscape is evolving beyond cytokine release syndrome and conventional ICANS. Prolonged cytopenias, impaired immune reconstitution, and severe or opportunistic infections further contribute to late morbidity and non-relapse mortality. Particular concern is emerging around delayed, persistent, and potentially progressive neurologic complications occurring beyond the conventional timeframe and clinical spectrum of ICANS. These include movement disorders, cognitive impairment, peripheral neuropathies, and other late neurotoxicity syndromes whose incidence, mechanisms, natural history, and optimal management remain poorly defined. Despite growing recognition of these complications, reliable predictors remain limited. Available risk scores and biomarkers primarily address acute CRS and ICANS and frequently lack validation across diseases, therapeutic platforms, and clinical settings.
This Poster Walk will highlight emerging toxicities and their clinical, biological, and treatment-related predictors. Particular attention will be given to artificial intelligence and machine-learning approaches that can integrate clinical, inflammatory, metabolic, immunologic, product-related, and longitudinal data, uncover complex risk patterns, and generate dynamic prediction models beyond individual biomarkers. These models could enable personalized surveillance, preventive interventions, outpatient treatment, early discharge, and timely escalation of care.
Chair:
Mirko Farina, MD, PhD
University of Brescia
Brescia, Italy
Willem Fibbe, MD, PhD
Leiden University Medical Center
Leiden, Netherlands
Speakers:
Daniel Landsburg, MD
Philadelphia, PA
Real-World Long-Term Safety and Efficacy of Tisagenlecleucel in Relapsed or Refractory Follicular Lymphoma from the CIBMTR Registry
Shatha Farhan, MD
Detroit, MI
Predicting Early CAR T-Cell Toxicity in DLBCL Using Machine Learning: An Internally Validated CIBMTR Registry Study
Tomasz Buczek, MPharm
Walbrzych, Poland
Cytomegalovirus End-Organ Disease Is More Strongly Represented with BCMA Bispecific Antibodies than with BCMA CAR-T in Eudravgilance
Weili Sun, MD, PhD
Los Angeles, CA
Does Continuous Immunoglobulin Replacement (IgRT) Reduce the Risk of High-Grade Infections with Bispecific Antibody (BsAb) Therapy in Relapsed/Refractory Multiple Myeloma (RRMM): A Marginal Structural Model (MSM) Analysis of MajesTEC-3 and MajesTEC-9
Ashvin Rajeev Pillai, MD
Dover, DE
Delayed Neurotoxicity After BCMA- and GPRC5D-Directed Therapy Exhibits Distinct Product- and Target-Specific Phenotypes: A Phenotype-Level Systematic Review and Evidence Synthesis
ASH Poster Walk on Innovations in Hemostasis and Thrombosis Clinical Research Design Hosted by Blood Vessels, Thrombosis & Hemostasis
This Poster Walk will address the critical need of strengthening understanding and application of rigorous, clinical trial design and statistical methodology for classical hematology research. Using hemostasis and thrombosis studies, the Poster Walk will showcase how trial design, epidemiologic approaches, and advanced statistical methods can improve the quality, interpretability, and impact of clinical research. The Walk will feature three posters with the author providing an 8-minute presentation, followed by a 5-minute expert methodological discussion led by an invited biostatistician. These commentaries will clarify the rationale for key design and analytic decisions, highlight innovative approaches, and translate technical concepts into practical lessons for clinicians, investigators, and trainees.
Chair:
Lisa Baumann Kreuziger, MD, MS
Medical College of Wisconsin
Milwaukee, WI
Keith McCrae, MD
The Cleveland Clinic Foundation
Cleveland, OH
Sara Vesely, PhD, MPH
The University of Oklahoma, Harold Hamm Health Campus
Oklahoma City, OK
Speakers:
Samuel Short, MD
Chapel Hill, NC
Stability and Predictive Utility of Published Polygenic Risk Scores for VTE Among Factor V Leiden Heterozygotes
Ecem Kalemoglu, MD, PhD
New Brunswick, NJ
Comparative Effectiveness and Safety of Anticoagulants After VTE in Severe Obesity With and Without Active Solid Tumor Malignancy
ASH Poster Walk on Leukemia in Latin America: Outcomes and Access to Diagnostics and Therapies Hosted by Blood Global Hematology
Leukemia outcomes in Latin America are shaped not only by disease biology, but also by profound variation in access to timely diagnosis, molecular testing, supportive care, novel therapies, transplantation, and clinical trials. Despite the region’s diverse population, Latin American patients remain underrepresented in major datasets, and differences in treatment delivery and survival are often obscured when evidence is derived primarily from high-income settings. This Poster Walk will highlight emerging studies that define these gaps, evaluate real-world outcomes, and present scalable strategies to improve diagnostic and therapeutic access across the region.
This Poster Walk will benefit investigators by consolidating perspectives on epidemiology, health-system barriers, genomic characterization, treatment availability, and implementation science. By comparing experiences across countries and institutions, the selected posters can identify shared challenges while providing opportunities for collaboration. The interactive format will allow attendees to discuss which interventions are transferable, how locally generated data can guide policy and clinical practice, and how international collaborations can be structured. Participants will leave with a clearer understanding of leukemia care in Latin America, practical models for expanding precision diagnostics and research infrastructure, and opportunities to develop collaborations that improve access and outcomes for these patients.
Chair:
Samuel Urrutia, MD, MS
Washington University in St. Louis
St. Louis, MO
Jorge Cortes, MD
University of Alabama at Birmingham
Birmingham, AL
Speakers:
Fausto Rios-Olais, MD
Mexico City, Mexico
Not All Hispanics Are the Same: Germline Genetic Ancestry Predicts Minimal Residual Disease Response in Acute Lymphoblastic Leukemia
Katia Pagnano, MD, PhD
Campinas, Brazil
Predictors of Successful Treatment-Free Remission (TFR) in Chronic Myeloid Leukemia: Results from Two Prospective Tyrosine Kinase Inhibitors (TKI) Discontinuation Trials
Melina Gisel Luft, MD
Ciudad Autonoma de Buenos Aires, Argentina
Real-World Outcomes and Treatment Heterogeneity in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Across Centers in Latin America
Luiza Viza Fonseca, MD
São Paulo, Brazil
Fusion-Aware Genomic Profiling Reclassifies Apparently Isolated Signaling Mutations in 8,458 Patients with Acute Myeloid Leukemia
Jule Franve Vasquez, MD
Lima, Peru
Early Mortality Drives Poor Outcomes in Adults with Acute Lymphoblastic Leukemia Treated with a CALGB 10403-Based Pediatric-Inspired Regimen in Peru
ASH Poster Walk on New Developments in Targeted Therapies for Myeloid Malignancies Hosted by Blood Neoplasia
Molecularly targeted approaches to myeloid malignancies have begun to impact clinical practice. Specifically targeted therapies including IDH inhibitors, menin inhibitors, and new strategies directed at NPM1-mutated acute myeloid leukemia as well as TP53-mutated disease continue to be developed. Even for those agents approved by regulatory agencies, optimal utilization strategies have not been defined; particularly in terms of combinatorial approaches, and earlier stage disease. Thus, for the physician practicing in this space, the developing armamentarium can be daunting and confusing. For the clinical investigator, understanding the landscape and the metrics for burden of proof to establish benefit represent critical foundations. This Poster Walk will be chosen from studies of the most interesting new molecularly-directed monotherapies as well as combinatorial studies and studies in earlier lines of treatment for established targeted agents. The walk will provide the audience with a perspective on the current state of drug development in AML, MDS, and MPN, and provide a critical framework for assessing the data.
Chair:
Steven Gore, MD
National Institutes of Health
Bethesda, MD
Jonathan Licht, MD
Van Andel Institute
Grand Rapids, MI
Speakers:
John Hatcher, PhD
Boston, MA
Targeted Degradation of BTK, HCK, and LYN by a Novel PROTAC DFCI-002-06 Suppresses Compensatory Survival Signaling and Enhances FLT3 Inhibitor Activity in FLT3-ITD Acute Myeloid Leukemia
Itallia Pacentine, PhD, MSc
Portland, OR
PU.1 Inhibition Sensitizes Stem-Monocytic Acute Myeloid Leukemia to BCL2 Blockade
Aditi Chatterjee, PhD
Baltimore, MD
The Novel Pan-RAS Inhibitor ADT-007 Synergizes with FLT3 Inhibitors in FLT3-ITD AML Cells with RAS Activation Driven by Mutations or Constitutive FLT3-ITD Signaling
Sofie Subiaur, MD, PhD
Stony Brook, NY
Momelotinib Inhibits MYC and MCL-1 and Enhances Venetoclax Sensitivity in Acute Myeloid Leukemia
Mael Heiblig, MD
Lyon, France
ODYSSEY: A First-in-Human Study of the Aldehyde Dehydrogenase (ALDH) Inhibitor ABD-3001 in Patients with Refractory/Relapsed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
ASH Poster Walk on Population Health and Access to Care
This Poster Walk will highlight works that investigate structural barriers impacting provision of care and approaches to extend access to optimal care for hematology patients. The walk will spotlight research that furthers efforts to overcome health disparities across populations. Featured posters will outline research that addresses and mitigates care delivery challenges, particularly those which disproportionately impact underserved or special populations. The walk will also serve to connect stakeholders in population health in hematology and facilitate discussions on the state of population health research in the field.
Chair:
Warren Fingrut, MD, MPH
MD Anderson Cancer Center
Houston, TX
Speakers:
Garth Rauscher, PhD
Chicago, IL
Racial Disparities in Access to Allogeneic Stem Cell Transplant (ASCT) in Acute Myeloid Leukemia (AML) Are Partly Mediated by Structural Racism and Health Insurance
Somya Khare, MD
New York, NY
Challenges in Access to Hematopoietic Cell Transplantation for Patients with Acute Myeloid Leukemia: A Prospective Study of Social Drivers of Health
Laura Rolke, PhD, MPH
Charlotte, NC
County-Level Debt in Collections Is Associated with Inferior Five-Year Survival in Adolescents and Young Adults with Acute Lymphoblastic Leukemia
Abigail Newell, PhD
Lansing, MI
Caregiving Is a “Full-Time Job”: Identifying Persistent Barriers to CAR T-Cell Therapy from a Mixed Methods Study of Healthcare Providers, Patients, and Caregivers
Kristine Karvonen, MD, MS
Seattle, WA
Medical Mistrust and Challenging Relationships with Providers Among Caregivers of Children with Cancer
68th ASH Annual Meeting and exposition
Registration for ASH members, non-members, groups, exhibitors, and media is now open!